A Phase 3 interventional study of Tizanidine and MI-Opioid Taper in Chronic Pain, Back Pain and Neck Pain, sponsored by Stanford University. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Stanford University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Chronic Pain by Stanford University — 14 open to participants now, 18 under way, 1 of them phase 3. Chronic Pain · Stanford University.
Among the 47 studies in Chronic Pain by Stanford University, this one is the 5th largest by planned enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 14 of the 17 other live ones, and was the 37th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →14 of the 47 studies in Chronic Pain by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+ · Women only
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 12–18
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 375 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 37 interventional studies, 259 across the 10 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
9 of the studies in Chronic Pain by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06867757Stanford UniversityTargeted Realtime Assessment of Chronic Pain in Youth | 2026-11 |
| NCT06317636Stanford UniversityPropofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression | 2026-11 |
| NCT04546685Stanford UniversityVirtual 1-Session Spanish "Empowered Relief" Group Intervention for Chronic Pain | 2026-12-31 |
| NCT07832240Stanford UniversityEmpowered Relief for Severe Pain After Cesarean Delivery During the Inpatient Period | 2027-01-15 |
| NCT07799883Stanford UniversityReducing Chronic Pain Following Cesarean Delivery | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 47 studies in Chronic Pain by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether a combined behavioral and pharmacologic intervention can help reduce opioid use, improve pain recovery, and prevent opioid misuse after surgery in adults undergoing elective surgery. The study includes adults aged 18 to 75 who have a history of long-term opioid use, defined as having access to opioids for 60 or more days within the 180 days before surgery.
The main questions it aims to answer are:
Researchers will compare MI-Opioid Taper + Tizanidine to MI-Opioid Taper with placebo and to EUC to see whether the intervention improves postoperative opioid and pain outcomes.
Participants will:
Be randomly assigned 7-13 days after surgery to one of three groups:
This is a Type 1 hybrid effectiveness-implementation, three-arm, parallel randomized controlled trial (RCT) evaluating a behavioral-pharmacologic intervention for postoperative opioid management in patients with preoperative long-term opioid use (LTOU). A total of 375 participants will be enrolled across four academic medical centers:
Eligible participants will be randomized in equal allocation to one of three study conditions:
The primary endpoint is time to return to baseline opioid use. Secondary endpoints include time to opioid cessation, time to opioid dispensing cessation, time to pain cessation, and incidence of postoperative opioid misuse. Additional exploratory analyses will examine behavioral and clinical mediators of treatment effects, including motivation for change, change talk, and pain reduction.
Effect modification analyses will assess whether baseline participant characteristics are associated with differential treatment engagement and outcomes. Implementation outcomes will be evaluated using a mixed-methods approach guided by the RE-AIM framework, focusing on barriers and facilitators to future dissemination and scalability of the MI-Opioid Taper intervention.
This project addresses a critical gap in postoperative care for patients with long-term opioid use in need of precision postoperative pain care to minimize opioid-related harms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Scheduled for elective surgery at
On the preoperative Baseline assessments, least one of the following:
Modified Brief Pain Inventory (mBPI): "Yes" to at least one of the following:
EXCLUSION CRITERIA
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tizanidine · Behavioral: MI-Opioid Taper
Behavioral: MI-Opioid Taper · Drug: Placebo
Behavioral: Enhanced Usual Care
Tizanidine 2mg three times a day for 5 weeks after surgery
Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
1 tablet three times a day for 5 weeks after surgery
Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
Time to Baseline Opioid Use
Defined as the first of two consecutive reports of return to preoperative daily MME or lower on the modified Brief Pain Inventory (mBPI) or the Recent Opioid Medication Use survey. Preoperative daily MME use is defined as average daily MME assessed during the Preoperative Call in the 1-5 day window prior to surgery.
Time frame: From Postoperative Day 7 through Postoperative Day 365
Time to Complete Opioid Cessation
First of two consecutive reports of opioid cessation on the modified Brief Pain Inventory (mBPI) or the Recent Opioid Medication Use survey.
Time frame: From Postoperative Day 7 through Postoperative Day 365
Time to Opioid Dispensing Cessation
Via state Prescription Drug Monitoring Program (PDMP): First day in the first gap in opioid prescribing ≥ 30 days after surgery
Time frame: From Postoperative Day 7 through Postoperative Day 365
Started Dec 2024 (actual). Primary completion is estimated for Jan 2028, 37 months after the start.
Of 49 phase 3 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tizanidine